Sigma-Aldrich Corporation has announced that the Cerilliant brand within its Applied Diagnostics and Testing business segment has introduced six new certified Snap-N-Spike reference standards of designer psychedelics in the NBOMe (N-methoxybenzyl-substituted) class of phenethylamines. New products include 25I-NBOMe HCl, 25C-NBOMe HCl, and 25B-NBOMe HCl and their deuterium labeled internal standards.
NBOMe phenethylamine derivatives represent a potentially lethal class of designer drugs with psychedelic and psychostimulant effects similar to LSD. Worldwide, increased production and sale of counterfeit hallucinogens laced with NBOMe derivatives have contributed to rising incidence of acute NBOMe toxicity. Individuals suffering from acute NBOMe toxicity have been reported to experience severe adverse health effects including metabolic acidosis, tachycardia, organ failure, and, in some instances, death.
Regulatory agencies are responding to the threat posed by the growing use and harmful effects of these new NBOMe designer drugs. In fall 2013, the U.S. Drug Enforcement Administration (DEA) temporarily placed 25I-NBOMe, 25C-NBOMe, and 25B-NBOMe into Schedule I of the Controlled Substances Act.
Cerilliant’s latest NBOMe reference standards complement its current offering of Certified Spiking Solutions for phenethylamines and their internal standards, including the 2C amines, dibenzofurans, and D amphetamines. Since these compounds are classified as controlled substances, Cerilliant supplies its Certified Spiking Solutions of NBOMe phenethylamines in a quantitative USDEA- and Health Canada-exempt solution. Cerilliant’s reference standards are manufactured and certified to industry standards, including ISO Guide 34, ISO/IEC 17025, and ISO 13485. They are suitable for a wide variety of quantitative or qualitative applications from control or calibrator preparation in forensic analysis or clinical toxicology testing to urine drug analysis and isotope dilution methods. Learn more about Cerilliant’s certified reference materials.Read more